Denise Mueller is currently the Chief Business Officer and Member of the Management Board at Affimed, an international biotech company. She has built a strong reputation for developing high-impact strategies, structures, teams, and alliances that have fueled business results, driven impact to stock value, and created market expansion across multiple therapeutic areas. In her current role, within the last 2 ½ years Denise led the capture of $156M in up-front cash payments through business development and advanced the company’s position as a pioneer in immuno-oncology. She secured strategic collaborations with Genentech and Roivant, in addition to clinical and pre-clinical collaborations with Merck, Roche, NKMax, and Artiva. Concurrently, as the President of Affimed US, Denise built the US organization to operationalize and scale the business. Denise has been instrumental in architecting and implementing the global corporate culture framework to strengthen cohesiveness of teams in multiple countries.
For small biotech companies that are always raising money, business development is a critical next step. Joining with a credible partner goes a long way in validating technology and platforms and gives small biotech companies the runway needed to grow.